Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in Suzhou, has announced a wall poster presentation showcasing the latest data for its FAK/ALK/ROS1 inhibitor APG-2449 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
The study determined the recommended Phase II dosage (RP2D) of APG-2449 to be 1200 mg daily. In the study, ROS1 and ALK positive non-small cell lung cancer (NSCLC) patients without prior TKI treatment (n=36) achieved objective response rates (ORR) of 68.2% (15/22) and 78.6% (11/14), respectively. Among the 22 NSCLC patients who were resistant to second-generation ALK TKI treatment and lacked targeted bypass gene mutations, 10 patients achieved partial response (PR), representing a 45.5% response rate. Among patients receiving RP2D treatment, 12 had baseline brain metastases, and 9 of these achieved intracranial lesion PR, with an ORR of 75.0%. APG-2449 demonstrated a favorable overall safety profile.- Flcube.com
